The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The high price of anticancer drugs: origins, implications, barriers, solutions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Ramsey, S. D., Bansal, A., Fedorenko, C. R., Blough, D. K., Overstreet, K. A., Shankaran, V., & Newcomb, P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.6620 · Cited by 912
Bower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
Ramsey, S., Blough, D., Kirchhoff, A., Kreizenbeck, K., Fedorenko, C., Snell, K., Newcomb, P., Hollingworth, W., & Overstreet, K. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1263 · Cited by 699
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Badwe, R., Hawaldar, R., Nair, N., Kaushik, R., Parmar, V., Siddique, S., Budrukkar, A., Mittra, I., & Gupta, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00135-7 · Cited by 592
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Pricing in the Market for Anticancer Drugs
Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M. (2015) · Journal of Economic Perspectives · doi:10.1257/jep.29.1.139 · Cited by 444
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach, P. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmhpr0807774 · Cited by 390
Bias in published cost effectiveness studies: systematic review
Bell, C. M., Urbach, D. R., Ray, J. G., Bayoumi, A., Rosen, A. B., Greenberg, D., & Neumann, P. J. (2006) · BMJ · doi:10.1136/bmj.38737.607558.80 · Cited by 382
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
The importance of new companies for drug discovery: origins of a decade of new drugs
Kneller, R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3251 · Cited by 344
The $2.6 Billion Pill — Methodologic and Policy Considerations
Avorn, J. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500848 · Cited by 318
Fojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Self-citationFive Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Mailankody, S., & Prasad, V. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0373 · Cited by 300
Self-citationPatient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
The Role of Public-Sector Research in the Discovery of Drugs and Vaccines
Stevens, A. J., Jensen, J. J., Wyller, K., Kilgore, P. C., Chatterjee, S., & Rohrbaugh, M. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1008268 · Cited by 244
What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?
Sampat, B. N., & Lichtenberg, F. R. (2011) · Health Affairs · doi:10.1377/hlthaff.2009.0917 · Cited by 190
The story of taxol: nature and politics in the pursuit of an anti-cancer drug
(2001) · Choice Reviews Online · doi:10.5860/choice.39-0970 · Cited by 182
Vogler, S., Vitry, A., & Babar, Z.-U.-D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00449-0 · Cited by 175
Food Price and Diet and Health Outcomes: 20 Years of the CARDIA Study
Duffey, K. J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.545 · Cited by 172
Cherny, N., Sullivan, R., Torode, J., Saar, M., & Eniu, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw213 · Cited by 172
Chen, Q., Jain, N., Ayer, T., Wierda, W. G., Flowers, C. R., O’Brien, S. M., Keating, M. J., Kantarjian, H. M., & Chhatwal, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2856 · Cited by 169
Goldstein, D. A., Chen, Q., Ayer, T., Howard, D. H., Lipscomb, J., El‐Rayes, B. F., & Flowers, C. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4904 · Cited by 165
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
Tefferi, A., Kantarjian, H. M., Rajkumar, S. V., Baker, L. H., Abkowitz, J., Adamson, J. W., Advani, R. H., Allison, J. P., Antman, K. H., Bast, R. C., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.001 · Cited by 145
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
Sanoff, H. K., Chang, Y., Lund, J. L., O’Neil, B. H., & Dusetzina, S. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0478 · Cited by 139
Padula, W. V., Larson, R. A., Dusetzina, S. B., Apperley, J. F., Hehlmann, R., Baccarani, M., Eigendorff, E., Guilhot, J., Guilhot, F., Hehlmann, R., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw003 · Cited by 130
Winn, A. N., Keating, N. L., & Dusetzina, S. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4184 · Cited by 127
Durkee, B. Y., Qian, Y., Pollom, E. L., King, M. T., Dudley, S. A., Shaffer, J. L., Chang, D. T., Gibbs, I. C., Goldhaber‐Fiebert, J. D., & Horst, K. C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9105 · Cited by 119
Dusetzina, S. B. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0648 · Cited by 112
Out-of-Pocket Costs and Oral Cancer Medication Discontinuation in the Elderly
Kaisaeng, N., Harpe, S. E., & Carroll, N. V. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.7.669 · Cited by 108
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
Goldstein, D. A., Ahmad, S. B., Chen, Q., Ayer, T., Howard, D. H., Lipscomb, J., El‐Rayes, B. F., & Flowers, C. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.9569 · Cited by 101
Systematic Review: Reliability of Compendia Methods for Off-Label Oncology Indications
Abernethy, A. P., Raman, G., Balk, E. M., Hammond, J. M., Orlando, L. A., Wheeler, J. L., Lau, J., & McCrory, D. C. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-5-200903030-00107 · Cited by 96
Mitchell, A. P., Harrison, M. R., Walker, M. S., George, D. J., Abernethy, A. P., & Hirsch, B. R. (2015) · Journal of Oncology Practice · doi:10.1200/jop.2015.004929 · Cited by 90
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
Paggio, J. C. D., Biju Azariah, M., Sullivan, R. J., Hopman, W. M., James, F. V., Roshni, S., Tannock, I. F., & Booth, C. M. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw538 · Cited by 90
Peters, E. M., Klein, W. M. P., Kaufman, A. R., Meilleur, L. R., & Dixon, A. (2013) · Social Issues and Policy Review · doi:10.1111/j.1751-2409.2012.01045.x · Cited by 79
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
Hill, A. M., Gotham, D., Fortunak, J., Meldrum, J., Erbacher, I., Martin, M., Shoman, H., Levi, J., Powderly, W. G., & Bower, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009586 · Cited by 77
Prasad, V. K., Massey, P. R., & Fojo, T. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0204 · Cited by 72
Self-citationPerspectives on Cost and Value in Cancer Care
Saltz, L. B. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4191 · Cited by 52
Variations in Time of Market Exclusivity Among Top-Selling Prescription Drugs in the United States
Wang, B., Liu, J. S., & Kesselheim, A. S. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7968 · Cited by 46
Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy
Biggers, A., Shi, Y., Charlson, J. A., Smith, E. C., Smallwood, A. J., Nattinger, A. B., Laud, P. W., & Neuner, J. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3350 · Cited by 44
Saret, C. J., Winn, A. N., Shah, G. L., Parsons, S. K., Lin, P., Cohen, J. T., & Neumann, P. J. (2015) · Blood · doi:10.1182/blood-2014-07-592832 · Cited by 42
Generic Drug Approvals Since the 1984 Hatch-Waxman Act
Gupta, R. M., Kesselheim, A. S., Downing, N. S., Greene, J. A., & Ross, J. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3411 · Cited by 40
‘Government Patent Use’: A Legal Approach To Reducing Drug Spending
Kapczynski, A., & Kesselheim, A. S. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1120 · Cited by 39
Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices
Mailankody, S., & Prasad, V. K. (2016) · JAMA · doi:10.1001/jama.2016.5998 · Cited by 29
Self-citationState Initiatives to Control Medication Costs — Can Transparency Legislation Help?
Sarpatwari, A., Avorn, J., & Kesselheim, A. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1605100 · Cited by 29
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem
Prasad, V. K., & Mailankody, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.028 · Cited by 27
Self-citationUsing a Drug-Safety Tool to Prevent Competition
Sarpatwari, A., Avorn, J., & Kesselheim, A. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1400488 · Cited by 25
Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine
Prasad, V. K., Kumar, H., & Mailankody, S. (2015) · Journal of Global Oncology · doi:10.1200/jgo.2015.000885 · Cited by 13
Self-citationFDA rejects first cognitive claim for antidepressant
Mullard, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.92 · Cited by 12
Addressing the quality of the ESMO-MCBS
Paggio, J. C. D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx077 · Cited by 8
Cited by
Advances in Oral Drug Delivery
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618411 · Cited by 876
Prasad, V., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 503
Self-citationPriorities for cancer research in low- and middle-income countries: a global perspective
Pramesh, C. S., Badwe, R. A., Bhoo-Pathy, N., Booth, C. M., Chinnaswamy, G., Dare, A. J., de Andrade, V. P., Hunter, D. J., Gopal, S., Gospodarowicz, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01738-x · Cited by 434
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
Endophytic Fungi—Alternative Sources of Cytotoxic Compounds: A Review
Uzma, F., Mohan, C. D., Hashem, A., Konappa, N. M., Rangappa, S., Kamath, P. V., Singh, B. P., Mudili, V., Gupta, V. K., Siddaiah, C. N., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00309 · Cited by 293
Metadata
- Authors
- Prasad, V., De Jesús, K., & Mailankody, S.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2017-03-14
- Volume
- 14
- Issue
- 6
- Pages
- 381-390
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2600333833
- Cited by
- 442
- References
- 60
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.